Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany

Endocrinology

Endocrinology
Specialized therapies in targeted indications
We are committed to making a real difference in the lives of patients with selected endocrine and metabolic disorders. We do this through our unique offering of specialized therapies in targeted indications along with innovative drug delivery devices designed to maximize their full potential.
We are applying our expertise to treat growth hormone deficiency in children and adults, as well as other related metabolic disorders. In the United States, our growth hormone is helping patients with HIV-associated wasting and short bowel syndrome; also in the US, we offer EGRIFTA™ (tesamorelin for injection) as the first and only treatment indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy (abdominal lipohypertrophy).
 

We have demonstrated our commitment to a rare metabolic disorder with a breakthrough therapy that allows those afflicted to lead a more normal life. In all of these areas, we are guided by our commitment to making a difference in the lives of patients and the people who care for them.

Disclaimer

The information contained in these pages is intended for general reference only. It may refer to pharmaceutical products, therapeutics or indications not yet registered or approved in a given country. This information should not be used to diagnose, treat, cure or prevent any disease without the advice of a qualified medical professional, and does not replace medical advice or a medical examination.

US Residents should consult EMD Serono, Inc. for information on products approved for sale in the United States of America.